A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.
Inclusion Criteria:
Exclusion Criteria:
CABA, C1025ABI, Argentina
Ciudad de Buenos Aires, C1181ACH, Argentina
Ciudad de Buenos Aires, C1428, Argentina
Beer Yaakov, 70300, Israel
Kurume-shi, 830-0011, Japan
Matsumoto-shi, 390-8621, Japan
Shinjuku-ku, 160-8582, Japan
Suita-shi, 564-8565, Japan
Lørenskog, N-1478, Norway
Santiago de Compostela-Coruña, 15706, Spain